Ophthalmic surgery, lasers & imaging retina · 2026
One-year Real-world Outcomes With Faricimab in Neovascular Age-related Macular Degeneration.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tabano David C, Ali Ferhina S, Borkar Durga S, Leng Theodore, Ahmed Ayesha, Ko Stella, Myrick Alayna, Zwick Erin, Downey Amanda, Barteselli Giulio, Singh Rishi P
Аннотация
BACKGROUND AND OBJECTIVE: This study evaluated real-world treatment patterns and 1-year outcomes in patients with neovascular age-related macular degeneration (nAMD) initiating faricimab.
PATIENTS AND METHODS: FARETINA-AMD was a retrospective study using data from the IRIS® Registry for patients diagnosed with nAMD initiating faricimab from February 2022 to March 2023.
RESULTS: Included in the study were 2,025 treatment-naive patients (2,184 eyes) and 22,253 patients (26,851 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Visual acuity improved by 2.0 ± 15.0 (mean ± SD) letters in treatment-naive eyes (P < .001) and was maintained in previously treated eyes at injection 7. Central subfield thickness (CST) improved by -53.1 ± 64.8 μm in treatment-naive and -28.5 ± 79.7 μm in previously treated eyes (both P < .0001); 78.4% and 66.8%, respectively, had achieved/maintained CST ≤ 280 μm at injection 7. Dosing frequency was reduced in the second 6 months (mean 2.4-3.2 injections) versus the first 6 months (4.0-4.2) of treatment.
CONCLUSION: Outcomes among patients with nAMD receiving faricimab over 1-year follow-up support the real-world effectiveness and extended durability of treatment.
PATIENTS AND METHODS: FARETINA-AMD was a retrospective study using data from the IRIS® Registry for patients diagnosed with nAMD initiating faricimab from February 2022 to March 2023.
RESULTS: Included in the study were 2,025 treatment-naive patients (2,184 eyes) and 22,253 patients (26,851 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Visual acuity improved by 2.0 ± 15.0 (mean ± SD) letters in treatment-naive eyes (P < .001) and was maintained in previously treated eyes at injection 7. Central subfield thickness (CST) improved by -53.1 ± 64.8 μm in treatment-naive and -28.5 ± 79.7 μm in previously treated eyes (both P < .0001); 78.4% and 66.8%, respectively, had achieved/maintained CST ≤ 280 μm at injection 7. Dosing frequency was reduced in the second 6 months (mean 2.4-3.2 injections) versus the first 6 months (4.0-4.2) of treatment.
CONCLUSION: Outcomes among patients with nAMD receiving faricimab over 1-year follow-up support the real-world effectiveness and extended durability of treatment.